Asphalion is the regulatory partner throughout the EU-funded H2020 project In2sight.
The goal of the project is to foster an unprecedented breakthrough in in-vivo optical imaging that will radically renew the biocompatibility tests of biomaterials, a technology that will recast our thinking of biomaterial validation, allowing unprecedented quantitative and longitudinal analyses of the host inflammatory response to the implant.
In2Sight is now on Twitter and we would like to invite you to follow the In2sight account to be up-to-date on the newest developments: @in2_sight
Additionally, you can also learn more on the project´s website:
For further information, you can contact us at: [email protected]
